Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Organisation › Details

Ablynx N.V. (Euronext Brussels: ABLX, Nasdaq: ABLX)

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. *


Period Start 2001-01-01 established
  Group Ablynx (Group)
Products Industry BIOTECH
  Industry 2 Nanobodies®
Persons Person Moses, Edwin (Ablynx 200603– CEO before non-exec Board Member 200411– before Oxford Asymmetry)
  Person 2 Heylen, Johan (Ablynx 201411– CCO before GSK + Servier + Wyeth)
Region Region Zwijnaarde
  Country Belgium
  Street 21 Technologiepark
  City 9052 Zwijnaarde
  Tel +32-9-262-0000
  Fax +32-9-262-0001
    Address record changed: 2015-11-26
Basic data Employees n. a.
  Currency EUR
  Annual sales 85,187,000 (income, total (2016) 2016-12-31)
  Profit -1,087,000 (2016-12-31)
  Cash 208,600,000 (2017-09-30)
    * Document for »About Section«: Ablynx N.V.. (7/20/17). "Press Release: Ablynx and Sanofi Enter into a Strategic Collaboration to Develop Nanobody Product Candidates Focused on Immune-mediated Inflammatory Diseases". Ghent.
Record changed: 2018-03-08


Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 600x60px

More documents for Ablynx (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

» top


Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Picture [LSE] – The Business Web Portal 120x600px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px